Here are four notes:
1. On Feb. 8, Oppenheimer cut Zimmer Biomet’s price target to $120.
2. Following the price target reduction, the shares hit $90.75 per share, down nearly 4.5 percent.
3. Since July 2015, Zimmer Biomet’s shares have decreased 12.18 percent.
4. The shares have underperformed the S&P 500 by 2.71 percent.
More articles on devices:
FDA schedules meeting to review Cartiva’s PMA for synthetic cartilage implant: 4 points
Zimmer Biomet investors to offer 11M+ shares of common stock: 5 takeaways
Stryker director sells 12k shares, soon after Sage Products acquisition & potential Moody’s downgrade: 7 points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
